Loading...
•
Mar 31, 2022
Sangamo Q1 2022 Earnings Report
Reported recent business highlights and first quarter 2022 financial results.
Key Takeaways
Sangamo Therapeutics reported a consolidated net loss of $44.0 million, or $0.30 per share, for the first quarter ended March 31, 2022. Revenues for the quarter were $28.2 million. The company continues to progress multiple programs through clinical development, including dosing the first patient in a study for kidney transplant rejection.
Dosed three additional Fabry disease patients, completing dose escalation for the Phase 1/2 study.
Dosed fifth sickle cell disease patient, the first with a product candidate manufactured using improved methods.
FDA lifted clinical hold on Hemophilia A trial; Pfizer expects to resume trial in Q3 2022.
Dosed first patient in renal transplant rejection study with engineered CAR-Treg cell therapy candidate.
Forward Guidance
Sangamo expects total operating expenses to be in the range of approximately $320 million to $350 million in 2022 on a GAAP basis. Non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, are expected to be in the range of approximately $280 million to $310 million in 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...